Watch Webinar

 

By clicking “Submit”, you agree that BioLegend may use this information to contact you about our programs, products or services; you may opt-out at any time.

Your personal data will be handled according to our Privacy Policy. In addition, if you are located within a Distributor Territory, you may be contacted directly by them. We never sell your data to anyone. To view, edit or delete your preferences or personal information, please fill out our Privacy Request Form.

Olsen Webinar

Webinar: New Checkpoint Molecules That Regulate Anti-Tumor Immunity

Dr. Vijay K. Kuchroo of Harvard Medical School and the Broad Institute describes using RNA and protein expression profiling at single-cell resolution to identify a module of co-inhibitory receptors, which includes not only several known co-inhibitory receptors (PD-1, Tim-3, Lag-3, and TIGIT), but also a number of novel surface receptors. This enabled functionally validating a number of novel co-inhibitory receptors not previously associated with T cell dysfunction. Studies with a number of “novel” co-inhibitory molecules in regulating anti-tumor immunity and autoimmunity will also be presented.

Explore:

  • What is the mechanism by which T cells are inhibited from inducing anti-tumor immunity?
  • Why doesn’t the “checkpoint” blockade induce complete anti-tumor immune response and tumor regression in all patients?
  • What are the soluble factors produced by T cells that inhibit anti-tumor immunity?

 

Bonus Video: Additional Q&A With Dr. Vijay Kuchroo:

Due to great interest in this talk, many submitted questions weren’t answered during the webinar. Dr. Kuchroo graciously answered these questions in a follow-up session.